Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts
This article was originally published in Scrip
Executive Summary
Move over Zarxio. There's a new kid in town: Inflectra (infliximab-dyyb), which won the FDA's nod on April 5 as the first monoclonal antibody biosimilar licensed in the US, although it's going to be a while before patients have access to the new drug, since Celltrion Inc. and Pfizer Inc. said they won't put it on the market until after June 29.
You may also be interested in...
Express Scripts Projects Higher Spending In Inflammation, Diabetes, Cancer
The three most expensive drug categories, on a per-member/per-year basis for the PBM's clients, increased by 19% or more in 2016, and similar growth is expected in the next three years. Per-patient spending on HCV drugs, however, declined by 34% last year.
2016 Review: Mixed Bag Of Hope, Setbacks For Korean Pharma
For the South Korean pharma industry, 2016 was largely about major global advances for a wide range of biosimilars, accompanied but some setbacks in the area of novel drug development.
Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Teva is looking to tap into $6.5bn in US sales of Herceptin and Rituxan in a new deal for North American rights to two of Celltrion's pipeline biosimilars for $160m upfront.